Loading...
•
Dec 31, 2020
Pacira Q4 2020 Earnings Report
Pacira BioSciences reported record full-year revenue and strong EXPAREL growth driven by anesthesia-driven regional approaches.
Key Takeaways
Pacira BioSciences reported Q4 2020 financial results with total revenues of $131.0 million, a 7% increase over Q4 2019. GAAP net income was $14.5 million, or $0.33 per share (basic) and $0.32 (diluted). Adjusted EBITDA was $42.9 million, a 48% increase over the prior year.
Total revenues were $131.0 million in the fourth quarter of 2020, a 7% increase over the fourth quarter of 2019.
EXPAREL net product sales were $125.3 million in the fourth quarter of 2020, a 7% increase over the fourth quarter of 2019.
GAAP net income was $14.5 million, or $0.33 per share (basic) and $0.32 (diluted), in the fourth quarter of 2020.
Adjusted EBITDA was $42.9 million in the fourth quarter of 2020, a 48% increase over the fourth quarter of 2019.
Revenue by Segment
Forward Guidance
The company’s 2021 product sales continue to be negatively impacted by the COVID-19 pandemic, which mandated significant postponement or suspension in the scheduling of elective surgical procedures resulting from public health guidance and government directives.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...